Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024. In the quarter to June 2026, revenue grew 16.5%, EPS fell 40.0%, free cash flow grew 31.6% and total debt rose 12.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

61.29 1.67 +2.80%
Market cap
$34.3B
P/E
42.3×
Fwd P/E
21.9×
Dividend yield
1.51%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
37/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 6
ROE
7.73% 7.69% 8.38% 8.42%
ROA
4.11% 4.07% 4.42% 4.26%
ROIC
5.44% 5.41% 5.43% 5.28%
Return on Tangible Assets
4.50% 4.51% 4.74% 4.69%
Average Days of Receivables
4.49 4.50 4.11 4.53
Free Cash Flow per Share
7.95 5.79 2.74 2.94
Free Cash Flow
3,432.44 2,489.82 1,195.57 1,310.08
Other line items

Show all line items

Columns are period end dates